Commercially relevant natural products and strategies to ensure quality

商业相关的天然产品和确保质量的策略

基本信息

  • 批准号:
    CCB21-2021-00120
  • 负责人:
  • 金额:
    $ 16.03万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Applied Research and Technology Partnership Grants
  • 财政年份:
    2022
  • 资助国家:
    加拿大
  • 起止时间:
    2022-01-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

Loyalist College will use ARTP funding to advance our work with small and medium-sized enterprises in the natural products and cannabis sectors. We will work with industry to overcome specific challenges such as a lack of research and standards to support product development, particularly for regulated and controlled substances, and chemistry challenges when working with natural products and/or cannabis, and unknown shelf-life and stability of products. Legal, political and complex societal factors have contributed to the limited fundamental and applied research required to better understand the complexity of plants in these sectors, and the practical challenges of developing products for the commercial market. Further, limited data is available on the compatibility of ingredients when designing new products, coupled with the uncertainty of the effects of processing, packaging, and storage on the active ingredients over time. This is a critical information gap that needs to be addressed for Canadians to be innovators in developing high-quality products, and for consumers to understand product implications. Our plan is to tackle this gap through focused industry-specific applied research projects. We will explore ingredient compatibility, test method specifications and controls, shelf life, and stability of products and packaging for the natural products and cannabis sectors. To do this we will create a research program intended to help meet the research and development (R&D) needs of companies that, in addition to other challenges, may lack financial resources or access to traditional funding or funding programs. Project results will be used to advance knowledge for these emerging sectors, support product development and commercialization, stimulate the economy and inform product guidelines and regulations. We will explore methods and controls that help produce higher quality, safer, and more consistent products and packaging for the natural products and cannabis sectors, to benefit Canadian consumers. Additionally, with viable and validated products and processes, companies will be in a better position to raise capital, attract investors, and pursue R&D funding for later stage development.
Loyalist College将使用ARTP资金来推进我们与天然产品和大麻行业中小企业的合作。我们将与行业合作,克服具体挑战,例如缺乏支持产品开发的研究和标准,特别是受管制和受控物质,以及天然产品和/或大麻的化学挑战,以及产品的保质期和稳定性未知。 法律的、政治的和复杂的社会因素导致了基础研究和应用研究的有限性,这些研究是更好地了解这些领域植物的复杂性所必需的,也是为商业市场开发产品的实际挑战。此外,在设计新产品时,有关成分相容性的数据有限,加上加工、包装和储存对活性成分的影响随时间的不确定性。这是一个关键的信息差距,需要解决加拿大人在开发高质量产品方面的创新,并为消费者了解产品的影响。 我们的计划是通过专注于特定行业的应用研究项目来解决这一差距。我们将探索天然产品和大麻行业的成分相容性,测试方法规范和控制,保质期以及产品和包装的稳定性。 为了做到这一点,我们将创建一个研究计划,旨在帮助满足公司的研究和开发(R&D)需求,除了其他挑战,可能缺乏财政资源或获得传统的资金或资助计划。项目成果将用于增进对这些新兴部门的了解,支持产品开发和商业化,刺激经济,并为产品指导方针和法规提供信息。我们将探索有助于为天然产品和大麻行业生产更高质量,更安全,更一致的产品和包装的方法和控制措施,以使加拿大消费者受益。此外,有了可行和经过验证的产品和工艺,公司将能够更好地筹集资金,吸引投资者,并为后期开发寻求研发资金。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kramp, Kari其他文献

Anxiolytic Activity of a Supercritical Carbon Dioxide Extract of Souroubea sympetala (Marcgraviaceae)
  • DOI:
    10.1002/ptr.3246
  • 发表时间:
    2011-02-01
  • 期刊:
  • 影响因子:
    7.2
  • 作者:
    Mullally, Martha;Kramp, Kari;Arnason, John Thor
  • 通讯作者:
    Arnason, John Thor

Kramp, Kari的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kramp, Kari', 18)}}的其他基金

Commercially relevant natural products and strategies to ensure quality
商业相关的天然产品和确保质量的策略
  • 批准号:
    CCB21-2021-00120
  • 财政年份:
    2021
  • 资助金额:
    $ 16.03万
  • 项目类别:
    Applied Research and Technology Partnership Grants

相似海外基金

Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
  • 批准号:
    10752046
  • 财政年份:
    2024
  • 资助金额:
    $ 16.03万
  • 项目类别:
Creation of a knowledgebase of high quality assertions of the clinical actionability of somatic variants in cancer
创建癌症体细胞变异临床可行性的高质量断言知识库
  • 批准号:
    10555024
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Regulation of human tendon development and regeneration
人体肌腱发育和再生的调节
  • 批准号:
    10681951
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
ClinEX - Clinical Evidence Extraction, Representation, and Appraisal
ClinEX - 临床证据提取、表示和评估
  • 批准号:
    10754029
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Genome Editing Therapy for Usher Syndrome Type 3
针对 3 型亚瑟综合症的基因组编辑疗法
  • 批准号:
    10759804
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Programming of Epigenetic Clocks and Biomarkers from Early-life Arsenic Exposure
生命早期砷暴露的表观遗传时钟和生物标志物的编程
  • 批准号:
    10726009
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
ALTERING THE IMMUNE LANDSCAPE TO AUGMENT BONE REGENERATION
改变免疫景观以增强骨再生
  • 批准号:
    10727797
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Marine sponge depsipeptides to minimize antibiotic collateral damage
海洋海绵缩酚肽可最大程度地减少抗生素的附带损害
  • 批准号:
    10726689
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Discovery and Development of a Benzoquinone Molecule as a Novel Anesthetic
苯醌分子作为新型麻醉剂的发现和开发
  • 批准号:
    10732956
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了